Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.35 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183162 | 0.98 | LMNA (0.46) | LMNACYP2C19SLC6A6BLML3MBTL1 | |
| SCHEMBL10886005 | 0.86 | APP (0.50) | LMNACYP2C19SLC6A6BLML3MBTL1 | |
| SCHEMBL28920803 | 0.83 | SLC6A5 (0.53) | LMNACYP2C19SLC6A6BLMAPP | |
| SCHEMBL30407466 | 0.83 | L3MBTL1 (0.47) | LMNACYP2C19SLC6A6BLML3MBTL1 | |
| SCHEMBL1492162 | 0.81 | LMNA (0.44) | LMNACYP2C19SLC6A6BLML3MBTL1 | |
| SCHEMBL3899861 | 0.80 | L3MBTL1 (0.39) | LMNACYP2C19SLC6A6BLML3MBTL1 | |
| SCHEMBL20226746 | 0.79 | CA2 (0.39) | LMNACYP2C19SLC6A6BLML3MBTL1 | |
| Zinc Ion SCHEMBL6913362 | 0.78 | L3MBTL1 (0.41) | LMNACYP2C19L3MBTL1CYP2D6CYP3A4 | |
| SCHEMBL3897865 | 0.78 | L3MBTL1 (0.38) | LMNACYP2C19SLC6A6BLML3MBTL1 | |
| SCHEMBL7204674 | 0.78 | CASP2 (0.52) | LMNACYP2C19L3MBTL1CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762174-B1 | BETA-ALETHINE WITH MELPHALAN OR CYCLOPHOSPHAMIDE; PREVENTS CLINICAL APPEARANCE OF A NEOPLASTIC OR PRE-NEOPLASTIC CONDITION; IMMUNOMODULATION; ENHANCING CELL GROWTH, VITALITY, DIFFERENTIATION; ANTISENESCENCE | DOVETAIL TECHNOLOGIES, INC. | 2004-07-13 | — | — | US | disclosed |
| US-6498150-B2 | USEFUL IN ENHANCING VACCINATION, INCREASING SYNTHESIS AND FUNCTION OF BLOOD CELL COMPONENTS, AND ENHANCING ANTITUMOR EFFECTS | DOVETAIL TECHNOLOGIES, INC. | 2002-12-24 | — | — | US | disclosed |
| US-6451853-B1 | Small molecules that elicit a polarized Th1 response and for modulation of cellular immunity | DOVETAIL TECHNOLOGIES, INC | 2002-09-17 | — | — | US | disclosed |
| US-20020035118-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | DOVETAIL TECHNOLOGIES INC. | 2002-03-21 | — | — | US | disclosed |
| US-6007819-A | Methods of inducing immunity using low molecular weight immune stimulants | DOVETAIL TECHNOLOGIES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999042099-A1 | LOW MOLECULAR WEIGHT COMPOUNDS ADMINISTERED TOGETHER WITH ANTI-CANCER AGENTS TO TREAT CANCER AND PHARMACEUTICAL COMPOSITIONS THEREOF | DOVETAIL TECHNOLOGIES INC. (US) | 1999-08-26 | — | — | WO | disclosed |
| WO-1999042097-A1 | SMALL MOLECULES THAT ELICIT A POLARIZED TH1 RESPONSE AND FOR MODULATION OF CELLULAR IMMUNITY | DOVETAIL TECHNOLOGIES INC. (US) | 1999-08-26 | — | — | WO | disclosed |
| WO-1997014306-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | DOVETAIL TECHNOLOGIES, INC. (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035118-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | ACP1, CD14, HPGDS | LMNA 3542/4885CYP2C19 4816/4885SLC6A6 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.